Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

3Total
P 1 (3)

Trial Status

Unknown3

Clinical Trials (3)

Showing 3 of 3 trials
NCT04058470Phase 1Unknown

Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

NCT04476459Phase 1Unknown

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

NCT04796857Phase 1Unknown

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Showing all 3 trials

Research Network

Activity Timeline